title: Sorafenib-induced Posterior Reversible Encephalopathy Syndrome in a Child With FLT3-ITD-positive Acute Myeloid Leukemia.
abstract: BACKGROUND
  Posterior reversible encephalopathy syndrome (PRES) is a clinical and radiologic condition characterized by headache, seizures, impaired vision, acute hypertension, and typical cranial MRI findings.
  
  
  METHODS
  A 10-year-old boy with FLT3-ITD-positive acute myelogenous leukemia who developed PRES during sorafenib treatment has been presented here. In English literature, there are 2 adult patients with metastatic cholangiocarcinoma or hepatocellular carcinoma who developed PRES under sorafenib treatment. Our patient is the first pediatric case with the diagnosis of acute myelogenous leukemia who developed PRES that might be attributed to sorafenib use.
  
  
  CONCLUSIONS
  Thus, PRES might be a rare, potentially serious, but manageable, side effect of sorafenib that should be kept in mind by pediatric hematologists and oncologists.
authors.affiliation: *Pediatric Hematology Unit †Hacettepe University Faculty of Medicine, Ihsan Dogramaci Children's Hospital, Sihhiye, Ankara, Turkey.
authors.forename: Betul
authors.initials: B
authors.lastname: Tavil
authors.forename: Fatma
authors.initials: F
authors.lastname: Isgandarova
authors.forename: Turan
authors.initials: T
authors.lastname: Bayhan
authors.forename: Sule
authors.initials: S
authors.lastname: Unal
authors.forename: Baris
authors.initials: B
authors.lastname: Kuskonmaz
authors.forename: Fatma
authors.initials: F
authors.lastname: Gumruk
authors.forename: Mualla
authors.initials: M
authors.lastname: Cetin
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D002648:Child; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000235:genetics; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D009536:Niacinamide / Q000009:adverse effects / Q000031:analogs & derivatives*; D010671:Phenylurea Compounds / Q000009:adverse effects*; D054038:Posterior Leukoencephalopathy Syndrome / Q000139:chemically induced*; D016879:Salvage Therapy / Q000379:methods; D000077157:Sorafenib; D051941:fms-Like Tyrosine Kinase 3 / Q000235:genetics*
chemical_list: D000970:Antineoplastic Agents; D010671:Phenylurea Compounds; D009536:Niacinamide; D000077157:Sorafenib; C497970:FLT3 protein, human; D051941:fms-Like Tyrosine Kinase 3